Biotech plunges 17% as cancer drug fails
Tuesday 16 February 1999
Shares in the beleaguered drug company plunged over 17 per cent to an all-time low of 21.5p after it admitted that Marimastat, one of its most advanced compounds, did not work in the treatment of pancreatic tumours.
Industry experts said the result cast doubts over Marismatat's efficacy and could jeopardise a major part of British Biotech's clinical programme.
The failure of the 400-patient test is a huge blow for the company as it had been predicted over 15 months ago by Andrew Millar, the group's former head of clinical trials.
Mr Millar was sacked in April for looking at confidential data in the trial - a procedure known as "unblinding" - and for expressing concerns to shareholders over the efficacy of marimastat and the anti-pancreatitis compound Zacutex.
The affair sparked a bitter row between Mr Millar and the board, which caused a collapse in the share price from its peak of over pounds 3 and led to the departure of the chief executive, Keith McCullagh.
Mr Millar yesterday said: "We knew this in December 1997. I feel terribly sorry that the right management of a potential new drug was not undertaken."
The new chief executive, Elliot Goldstein, yesterday said that the study's negative results did not spell the end of Marimastat.
He said the test showed that the drug had failed its target of a 16 per cent reduction in death rates compared with an existing drug. However, he said pancreatic cancer was one of the most difficult cancers to treat and that further studies were needed to assess Marimastat's efficacy.
British Biotech was spending around half of its pounds 24m development budget to trial the drug on different forms of cancer in nine other studies and results were expected over the next 12 month. "We are not deciding to quit. The plan is to bring the nine studies to their end," Dr Goldstein said.
Peder Jensen, the development director, denied that the failure of the trials vindicated Dr Millar's actions. He said that when Dr Millar unblinded the study, he could not have predicted the outcome because the data was too scant. "He just happened to be right," Mr Jensen said.
Mr Millar, who is embroiled in a legal case with the company set to be heard in the High Court later this year, rejected the suggestion. "It is a virtual mathematical certainty that this was to happen".
He predicted that the other study he unblinded, a key trial for Zacutex, was also set to fail. The company said it would report on the trial before the end of next month.
City analysts said the result of the trial would prompt investors to reduce their estimates of Marimastat's future earnings. The drug was once hailed as a potential blockbuster with estimated sales of over $1bn a year.
However, a series of setbacks has prompted experts to revise sales predictions to $200m.
- 1 Hair loss explained: How and why men go bald
- 2 Game of Thrones season 6: Jon Snow theorists believe the Stark may have a twin sister
- 3 Artist takes LSD, draws herself over different stages of the 9-hour trip to show its effects
- 4 A pint of water every day is the key to losing weight, scientists say
- 5 Russia 'accidentally reveals' number of its soldiers killed in eastern Ukraine
Most expensive city to live in for expatriates: Luanda, Angola takes number one spot with Hong Kong and Zurich in top three
If Surrey were Syria: Social experiment shows what it's like to live under siege
Video of Irish 'professional boxer' fighting Istanbul neighbourhood goes viral in Turkey
Irish tourist filmed fighting with shopkeepers in Turkey says they 'messed with the wrong man'
House of Lords: Outcry as donors, fixers and MPs caught up in expenses scandal get peerages
Dresden riots: Protesters in Germany attack refugee buses shouting 'foreigners out'
France train shooting: US soldiers speak of the moment they stopped gunman and 'beat him until he was unconscious'
Labour leadership: Jeremy Corbyn accused of 'deluding' young supporters with 'claptrap'
'Women only' train carriages: Jeremy Corbyn unveils radical move to tackle public harassment
Black holes are a passage to another universe, says Stephen Hawking
Iain Duncan Smith calls for urgent ESA overhaul as part of drive to cut down welfare costs
iJobs Money & Business
£20000 - £25000 per annum + competitive + incentives + uncapped comms: SThree:...
£13000 - £25000 per annum: Recruitment Genius: Would you like to be part of a ...
£20000 - £25000 per annum + competitive: SThree: Are you passionate about sale...
£25000 per annum + benefits: Ashdown Group: A large financial services company...